Related Experiment Video
Updated: May 10, 2025

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Development and Validation of Predictive Models for Inflammatory Bowel Disease Diagnosis: A Machine Learning and
Rongrong Dong1, Yiting Wang2, Han Yao1
1Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, 130021, People's Republic of China.
Background:
Inflammatory bowel disease (IBD) is a chronic, incurable gastrointestinal disease without a gold standard for diagnosis. This study aimed to develop predictive models for diagnosing IBD, Crohn's disease (CD), and Ulcerative colitis (UC) by combining two approaches: machine learning (ML) and traditional nomogram models.
Methods:
Cohorts 1 and 2 comprised data from the UK Biobank (UKB), and the First Hospital of Jilin University, respectively, which represented the initial laboratory tests upon admission for 1135 and 237 CD patients, 2192 and 326 UC patients, and 1798 and 298 non-IBD patients. Cohorts 1 and 2 were used to create predictive models. The parameters of the machine learning model established by Cohorts 1 and 2 were merged, and nomogram models were developed using Logistic regression. Cohort 3 collected initial laboratory tests from 117 CD patients, 197 UC patients, and 241 non IBD patients at a tertiary hospital in different regions of China for external testing of three nomogram models.
Results:
For Cohort 1, ML-IBD-1, ML-CD-1 and ML-UC-1 models developed using the LightGBM algorithm demonstrated exceptional discrimination (ML-IBD-1: AUC = 0.788; ML-CD-1: AUC = 0.772; ML-UC-1: AUC = 0.841). For Cohort 2, ML-IBD-2, ML-CD-2, and ML-UC-2 models developed using XGBoost and Logistic Regression algorithms demonstrated exceptional discrimination (ML-IBD-2: AUC = 0.894; ML-CD-2: AUC = 0.932; ML-UC-2: AUC = 0.778). The nomogram model exhibits good diagnostic capability (nomogram-IBD: AUC=0.778, 95% CI (0.688-0.868); nomogram-CD: AUC=0.744, 95% CI (0.710-0.778); nomogram-UC, AUC=0.702, 95% CI (0.591-0.814)). The predictive ability of the three models was validated in cohort 3 (nomogram-IBD: AUC=0.758, 95% CI (0.683-0.832); nomogram-CD: AUC=0.791, 95% CI (0.717-0.865); nomogram-UC, AUC=0.817, 95% CI (0.702-0.932)).
Conclusion:
This study utilized three cohorts and developed risk prediction models for IBD, CD, and UC with good diagnostic capability, based on conventional laboratory data using ML and nomogram.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:

